LATAM Healthtech VC: IP, Data, and Regulatory Risk

LATAM Healthtech VC: IP, Data, and Regulatory Risk

Healthtech is one of the fastest-growing investment sectors in Latin America, driven by vast underserved healthcare markets, the digitization of health records across the region, and the application of AI to clinical decision support, diagnostic imaging, and drug discovery. For VC funds with LATAM healthtech exposure, the IP and regulatory risk profile is the most complex in the tech sector — combining software IP risks, medical device regulatory requirements, clinical data governance, and the intersection of LGPD/LPDP with health data protection obligations.

This guide provides the LATAM healthtech-specific regulatory and IP framework for VC due diligence, covering the regulatory authorities, clinical data IP implications, AI/ML model ownership, and the specific compliance dimensions that differentiate healthtech investments from general tech.

LATAM Healthtech Regulatory Landscape

Health Data IP and Privacy Intersections

Health data creates particularly complex IP and privacy intersections for LATAM healthtech companies. Clinical records, genomic data, diagnostic images, and electronic health records simultaneously: (1) constitute personal data subject to LGPD/LPDP protection; (2) may constitute trade secrets if the data compilation has commercial value; (3) serve as training data for AI/ML models; and (4) are subject to specific health data protection requirements under national health laws.

Under Brazil's LGPD, health data is classified as dados pessoais sensíveis (sensitive personal data) — a category subject to stricter processing requirements. Article 11 of LGPD requires a specific legal basis for processing sensitive health data, with consent from the data subject as the primary basis. ANPD has been developing sector-specific guidance for health data processing that may impose additional requirements on healthtech companies.

The IP implications of health data training datasets are significant. A diagnostic AI model trained on clinical images constitutes an IP asset — but the training data (patient images) is sensitive personal data that cannot be retained beyond the processing need without a valid LGPD legal basis. This creates a tension between IP asset development (which benefits from larger training datasets retained over time) and data minimization obligations (which require limiting retention to what is necessary for the identified purpose).

AI Model IP Ownership in Healthtech

AI diagnostic models represent the core IP asset of many LATAM healthtech companies. Establishing clear ownership of these models requires addressing three IP layers:

1. Training data ownership or license — Who owns the clinical data used to train the model, and on what legal basis was it processed? Data contributed by hospital partners may be subject to data sharing agreements that affect the company's freedom to use derived models.
2. Model architecture — Many healthtech companies build on open source foundation models (TensorFlow, PyTorch, pre-trained transformer architectures). The open source license governing the foundation model affects the company's ability to commercialize the fine-tuned model — an AGPL v3 foundation model used in a deployed diagnostic service creates copyleft obligations that may require source disclosure.
3. Fine-tuning code and model weights — The company's proprietary fine-tuning code and the resulting model weights are the highest-value IP assets. These must be owned clearly by the company through appropriate IP assignments from all contributors (researchers, data scientists, clinical validation teams).

ANVISA Registration and IP Due Diligence

For Brazil healthtech companies requiring ANVISA registration, the regulatory process creates IP documentation requirements that overlap with investor IP due diligence. ANVISA's technical submission for SaMD registration requires description of the software's function, its safety and performance characteristics, and its development process — documentation that also supports the IP due diligence showing clear ownership and development history.

VC investors conducting due diligence on Brazil healthtech companies should verify: (1) ANVISA registration status for products that function as medical devices; (2) the regulatory strategy for products in development (pre-submission engagement with ANVISA); and (3) whether the company's IP documentation is consistent with the regulatory submissions already filed. Inconsistencies between regulatory submissions and IP ownership claims create complications for both regulatory compliance and IP due diligence.

Open Source in Healthtech: Elevated Risk

Open source software use in healthtech requires the same license compliance as in any tech sector, but with elevated stakes. An AGPL v3 violation in a diagnostic AI system that is subject to ANVISA oversight creates simultaneous regulatory, IP, and reputational risk. The copyleft compliance obligation — providing source code to users — may conflict with ANVISA's expectation that medical device software is controlled and validated by the manufacturer.

The WIPO framework and the TRIPS Agreement obligations apply to open source license enforcement in healthtech exactly as in any other sector. Healthtech companies should implement the same CI/CD open source compliance automation recommended for all startups — but with particular attention to the licenses governing AI/ML frameworks and medical imaging libraries.

Frequently Asked Questions

LATAM IP and Regulatory Resources

The following authoritative sources provide the legal and regulatory foundation for the topics covered in this guide. All LATAM jurisdictions are signatories to the WIPO treaties that form the international IP framework, and domestic laws implement TRIPS Agreement minimum standards.

• TRIPS Agreement — WIPO — The foundational international IP treaty binding all WTO member states, including Argentina, Brazil, Mexico, Colombia, Chile, and Peru.
• INPI Brazil — Brazil's National Institute of Industrial Property; administers software registration, patents, and trademarks under Lei 9.279/1996 and Lei 9.609/1998.
• INPI Argentina — Argentina's IP office; manages software registration under Ley 11.723 and trademark protection.
• Open Source Initiative License List — Authoritative catalog of OSI-approved open source licenses including GPL v2, GPL v3, AGPL v3, MIT, and Apache License 2.0.
• SPDX License List — Machine-readable license identifiers used in Software Bill of Materials (SBOM) generation and CI/CD compliance tooling.
• IMPI Mexico — Instituto Mexicano de la Propiedad Industrial; administers patents and trademarks under the LFPPI.

For startups operating across LATAM, compliance with LGPD (Brazil), LPDP (Argentina — Ley 25.326), LFPDPPP (Mexico), and the TRIPS Agreement framework is not optional. Each framework creates distinct obligations that require jurisdiction-specific legal review. Our fixed-price audit packages provide this review with 48-hour delivery, so your team can move quickly without sacrificing legal certainty.

WIPO and International Health IP Framework

LATAM healthtech companies benefit from strong international IP protection through WIPO's treaty framework. The Patent Cooperation Treaty (PCT) — administered by WIPO — allows healthtech startups to file a single international patent application designating multiple countries, providing 30 months to assess market potential before incurring the cost of national phase entry in each jurisdiction. For healthtech companies with genuinely novel technical inventions — medical device control algorithms with measurable clinical effects, novel drug delivery mechanisms implemented in software — PCT filing preserves patent rights internationally while allowing the startup to focus on regulatory approval and clinical validation before committing to country-specific patent prosecution costs.

The Berne Convention and TRIPS Agreement provide the copyright protection baseline for healthtech software — diagnostic AI models, clinical decision support systems, health record management applications. ANVISA's regulatory requirements for SaMD (software as a medical device) and the IP protection under Lei 9.609/1998 operate independently but complementarily: ANVISA registration demonstrates that the software is safe and effective as a medical device; INPI Brazil registration demonstrates that the software is owned by the company and legally protected. Both registrations together provide the complete regulatory and IP documentation package that institutional healthcare investors expect at Series A.

LGPD's classification of health data as sensitive personal data (dados pessoais sensíveis) creates compliance obligations that interact with the IP value of clinical datasets. A healthtech company that has built a proprietary clinical dataset through years of hospital partnerships and patient consenting has an IP asset — but one whose commercial exploitation is constrained by LGPD's purpose limitation and data minimization principles. The ANPD's ongoing development of health data guidance will define the boundaries of permissible commercial use of clinical datasets, including AI model training. Healthtech companies should engage with ANPD consultations and monitor published guidance to ensure their data strategy remains within regulatory bounds as the framework evolves.

For VC funds evaluating LATAM healthtech investments, the intersection of regulatory and IP risk requires specialized assessment that combines BCB/CNBV/SFC-equivalent ANVISA/COFEPRIS/ANMAT analysis with the standard IP due diligence framework. Our Full IP Due Diligence at $1,200 provides the IP dimension; our network of specialized LATAM healthcare regulatory counsel provides the ANVISA/COFEPRIS/ANMAT regulatory dimension. The WIPO arbitration center provides dispute resolution for international IP disputes involving LATAM healthtech companies. Contact us via WhatsApp or the meeting link below to discuss an integrated regulatory and IP assessment for your LATAM healthtech portfolio company.